
Background: Recent evidence suggests the initiation of rheumatoid arthritis (RA) – related autoimmunity may occur by local citrullination at the oral mucosa and lungs. IgA antibodies are the hallmark of mucosal immunity; the majority of saliva IgA antibodies are locally produced whereas IgG antibodies are largely serum derived(.1 Furthermore, IgA anti-CCP antibodies have recently been described in the sputum of at-risk individuals(.2 The relative importance of the oral and lung mucosa in disease initiation is, however, unclear and the prevalence of saliva and sputum anti-CCP antibodies in the same at-risk individuals has not been reported.
Objectives: To investigate the prevalence of IgA anti-CCP antibodies in the saliva and sputum of seropositive individuals at risk of developing RA.
Methods: Anti-CCP positive individuals with no evidence of clinical synovitis (CCP+), anti-CCP positive RA patients (RA) and healthy controls (HC) matched for age and smoking status were recruited. Unstimulated saliva and serum samples were collected. Induced sputum samples were obtained using 7% saline via ultrasonic nebuliser (UltraNeb 3000 DA, Devilbiss, Germany). Sputum was mixed with phosphate buffered saline, mechanically disrupted and centrifuged to obtain supernatant. IgA and IgG anti-CCP antibodies (anti-CCP2, immunocap assay, Phadia) were measured in all saliva, sputum and serum samples. IgA and saliva/sputum IgG anti-CCP titres exceeding the 95th centile in HC were considered positive.
Results: 55 CCP+, 40 RA and 32 HC were recruited and had saliva and serum collected. 24 CCP+, 14 RA and 22 HC had sputum and serum collected. Of these, 23 CCP +and 7 RA patients provided simultaneous saliva, sputum and serum samples. 8/55 (15%) CCP +and 10/40 (25%) RA patients had positive saliva IgA anti-CCP levels compared with 1/31 (3%) HC. 23/54 (43%) CCP +and 21/48 (44%) RA patients had positive serum IgA anti-CCP levels compared with 1/32 (3%) HC (table 1). Of note, 7/18 (39%) patients with a positive saliva IgA anti-CCP test had a negative serum IgA anti-CCP test, suggesting localised production and accumulation of IgA anti-CCP antibodies rather than transfer from the serum. Only 1/24 CCP+ (4%) and 1/14 (7%) RA patients had positive sputum IgA anti-CCP levels. No patients had IgA anti-CCP detectable in both saliva and sputum samples.
Anti-CCP positive results (%) |
||||||
|---|---|---|---|---|---|---|
Saliva IgA |
Sputum IgA |
Serum IgA |
Saliva IgG |
Sputum IgG |
Serum IgG |
|
HC |
1/31(3 |
1/22(5 |
1/32(3 |
1/31(3 |
0/22 (0) |
0/32 (0) |
CCP+at-risk |
8/55(15 |
1/24(4 |
23/54(43 |
23/54(43 |
10/24(42 |
50/54(93) |
RA |
10/40(25 |
1/14(7 |
21/48(44 |
23/42(55) |
9/14(64) |
47/48(98) |
Conclusions: We found an increased prevalence of saliva but not sputum IgA anti-CCP antibodies in seropositive at-risk individuals. These findings support the concept that localised RA-related autoimmunity in at risk individuals can be site specific. IgA anti-CCP antibodies at the oral mucosa precede arthritis and may represent an important step in the initiation and propagation of disease.
References
Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2018-eular.5287